

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天 辰 生 物

LongBio Pharma (Suzhou) Co., Ltd.

天辰生物醫藥(蘇州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1779)

**VOLUNTARY ANNOUNCEMENT
BLA FOR LP-003 FOR THE INDICATION OF SAR
HAS BEEN ACCEPTED BY THE NMPA**

This announcement is made by LongBio Pharma (Suzhou) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Group about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the biologics license application (“**BLA**”) for LP-003 for the indication of seasonal allergic rhinitis (“**SAR**”) has been accepted by the National Medical Products Administration of the People's Republic of China (“**NMPA**”).

ABOUT LP-003

LP-003 is an anti-IgE antibody with novel sequencing. LP-003 is targeted to treat allergic diseases, including SAR, CSU, allergic asthma, CRSwNP and food allergy. The primary function of LP-003 is to block free IgE in blood and tissues, and thus inhibiting the occurrence of IgE-driven allergic reactions. LP-003 has the capability to bind free IgE and prohibit those free and excessive IgE from binding to the high-affinity IgE receptor, FcεRI. IgE is the core mechanism driving Type I hypersensitivity. Type I hypersensitivity triggered by allergens in different organs causes SAR, allergic asthma, CSU, food allergy and other allergic diseases. Anti-IgE antibody currently plays a pivotal role in the treatment of a variety of allergic diseases due to its capabilities of inhibiting cascade of allergic reactions. Anti-IgE therapy has been included in Chinese guidelines for the diagnosis and treatment of SAR and CSU. We have obtained investigational new drug (“**IND**”) approvals and/or initiated clinical trials for LP-003 in China for various indications, including SAR, CSU, allergic asthma, CRSwNP and food allergy. The IND application for LP-003 for the indication of peanut allergy has also been approved by the United States Food and Drug Administration (FDA).

ABOUT THE COMPANY

The Company is a clinical-stage biopharmaceutical company. Established in 2020 and located in Shanghai and Changshu, Suzhou, China, the Company primarily focuses on in-house discovery and development of biopharmaceuticals targeting allergic and autoimmune diseases. The Group has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases.

The Company cannot guarantee that it will be able to develop and/or ultimately market LP-003 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
LongBio Pharma (Suzhou) Co., Ltd.
Dr. Liu Heng
Chairman of the Board and Executive Director

Hong Kong, August 21, 2026

As at the date of this announcement, the Board comprises (i) Dr. LIU Heng, Dr. SUN Bill Nai-chau and Mr. XIE Ming as executive Directors; (ii) Mr. LIN Jian, Ms. GU Qin, Dr. XUE Di and Dr. CHEN Kan as non-executive Directors; and (iii) Mr. SIU Paul Yu Hay, Mr. RUAN Tim, Mr. YANG Chun and Mr. ZHOU Guofang as independent non-executive Directors.